STEMCELL-TECHNOLOGIES
18.8.2021 12:02:03 CEST | Business Wire | Press release
STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use of tissue-derived organoids—including lung, intestinal, and liver organoids—for use in preclinical toxicology screening and non-cancer drug development services to be offered by the Contract Assay Services division of STEMCELL. These services will help researchers and organizations working on drug development incorporate organoids into their preclinical testing programs and bring new therapeutics to market faster and more cost-effectively.
HUB Organoids™ are experimental models derived from the adult stem cells present in epithelial tissues. Expansion and differentiation of these stem cells gives rise to functional “mini-organs in a dish”. HUB Organoids™ represent a patient-specific way of assessing the efficacy and toxicity of drugs during preclinical screening. By closely mimicking human biology, HUB Organoids™ can be used to more accurately predict patient response to treatment than traditionally used systems. As such, they have the potential to drastically lower the costs and failure rates currently associated with bringing new treatments to market. Under the existing agreement, STEMCELL develops and supplies a wide range of cell culture kits that efficiently expand and maintain the different stem cell-derived organoids that will be used for many of these screening programs.
This new agreement complements HUB and STEMCELL’s existing partnership, where STEMCELL is the exclusive provider of cell culture media for all HUB Organoids™, by allowing STEMCELL to perform preclinical toxicology screening as well as non-cancer drug testing and validation services. "We are extremely pleased to be able to expand our partnership with HUB to include these new services," remarked Dr. Allen Eaves, STEMCELL’s Founder, President, and CEO. "As Scientists Helping Scientists, our goal is to make these incredible technologies more accessible to researchers, whether they are growing organoids in their own labs or partnering with service providers to advance their science."
“At HUB we are on a mission to bridge the gap between the lab and the clinic and bring patients-specific models into the lab,” said Dr. Robert Vries, HUB CEO. “Carefully selecting our strategic partners is key to expanding global access to HUB Organoid Technology and, ultimately, to improving patient care. STEMCELL has already demonstrated thought leadership in the Organoid Technology field; therefore, we believe that expanding the scope of our partnership to include services will benefit the research and drug development community worldwide.”
About STEMCELL Technologies
As Scientists Helping Scientists, STEMCELL Technologies is committed to providing high-quality cell culture media, cell isolation products, accessory reagents and services for life science research. Driven by science and a passion for quality, STEMCELL Technologies offers over 2500 products designed to support the basic to translational research continuum. Visit www.stemcell.com to learn more.
About HUB
Hubrecht Organoid Technology (HUB) was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and Sciences (KNAW) to refine organoid development and foster organoid adoption globally. HUB Organoid Technology represents a paradigm-shift that bridges the gap between the lab and the clinic and effectively brings “patients in the lab” for drug discovery and development, preclinical patient stratification, predictive biomarker discovery, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics applications. Learn more by visiting www.huborganoids.nl
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005144/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
du and Comarch Communications Launch Agentic AI for OSS Network Operations28.10.2026 13:00:00 CET | Press release
du, the leading telecommunications and digital service provider and Comarch Communications, a global provider of Enterprise Tech solutions for connectivity, have expanded their partnership to lay the data foundation for goal-oriented autonomous execution. Comarch Communications is delivering a major upgrade to du’s Operational Support Systems (OSS) platform. By creating a unified central hub for all network data regardless of its source, the platform automatically keeps information up to date, giving du complete real-time visibility over its network resources. Justin Shields, CIO at du: “Our ambition at du is to raise the standard for operational agility while keeping the trust of our customers. Resilience and control are at the center of how we plan to scale AI. This next phase with Comarch Communications strengthens the inventory and topology foundation that underpins our vision for an enhanced customer experience, while enabling a new generation of AI-driven applications and workflo
Patsnap Launches AI Agents to Extract SAR Data and Identify Lead Compounds From Small Molecule Patents28.10.2026 13:00:00 CET | Press release
Lead Compound Analyzer and SAR Extractor help scientists identify likely lead compounds and turn patent-disclosed chemistry into structured, source-referenced data for drug discovery. Patsnap today announced Lead Compound Analyzer and SAR Extractor, two AI agents in Patsnap Eureka Life Sciences that help drug discovery teams identify likely lead compounds and extract structure-activity data from small molecule patents. By reducing manual extraction, the agents help medicinal chemistry, competitive intelligence and computational teams assess competitor compounds, compare chemical series and inform further research. Learn more here. AI is giving drug discovery teams new ways to analyze compounds and guide molecular design, but those workflows depend on the experimental data available to them. Patents are often an early public source of new compounds, potency data and structure-activity relationships, yet that evidence remains difficult to reuse. Compound structures appear as images, acti
NIQ Expands Shopper Experience Platform to Improve Product Discovery in AI-Powered Shopping28.10.2026 12:00:00 CET | Press release
New optimization capabilities and NIQ’s CONTENT Framework help brands strengthen product visibility, relevance and performance across retail and AI-powered shopping channels NielsenIQ (NYSE: NIQ)today announced new optimization capabilities for its Shopper Experience Platform, supported by its CONTENT Framework, a seven-pillar approach to evaluating and improving product content. Together, they enable brands to evaluate product content and imagery against retailer requirements and category expectations, identify gaps, and prioritize improvements that strengthen product discovery across retailer sites, search engines, and AI-powered shopping channels. A product can be accurate, complete, and retailer-compliant yet still be difficult for shoppers to find, understand, or choose. This challenge is growing as AI assistants, retailer algorithms, and recommendation engines play a larger role in shopping. According to NIQ's Consumer Outlook: Guide to 2027, 55% of global consumers report having
Tula Technology Signs Landmark Agreement Licensing Dynamic Motor Drive® to Global Tier 1 Supplier28.10.2026 12:00:00 CET | Press release
Agreement covers supplier’s full E-drive portfolio, creating global production opportunities Tula Technology, Inc., a leader in propulsion efficiency and developer of Dynamic Motor Drive® (DMD), today announced that it has signed an intellectual property license agreement with a global Tier 1 automotive supplier covering the supplier’s entire E-drive portfolio. Under the agreement, the Tier 1 supplier has a non-exclusive license to Tula’s DMD portfolio of patents covering the U.S., Europe, and Asia. The agreement marks the first commercial deployment of DMD spanning the supplier's complete E‑drive portfolio. DMD is an innovative software‑only technology that strategically applies torque pulses under optimal conditions, reducing drive‑cycle energy consumption by 0.5‑2.0%. Because DMD is implemented entirely in software, it requires no hardware changes or additions, allowing suppliers and OEMs to integrate the technology into existing E‑drive systems with minimal engineering effort. The
PayNet Enables Malaysian Mobile Banking App Users to Make Overseas DuitNow QR Payments via Alipay+28.10.2026 11:42:00 CET | Press release
Malaysians can now pay using supported local banking apps in five destinations: Chinese Mainland, Hong Kong SAR, South Korea, the Philippines and Laos. More markets will be added progressively. Payments Network Malaysia Sdn Bhd (PayNet) today announced the launch of outbound DuitNow QR payment connectivity through Alipay+, the unified wallet gateway of Ant International. Malaysians can now use supported local mobile banking apps to pay at participating Alipay+-supported merchants in five destinations: Chinese Mainland, Hong Kong SAR, South Korea, the Philippines and Laos. The initial three launch banks are Maybank, CIMB and Hong Leong Bank, with Bank Islam set to join soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028063575/en/ From left to right: Michael Guo, General Manager of Alipay+ SEA, ANZ and South Asia, Ant International; Praveen Rajan, Chief Executive Officer of PayNet; Danny Chung, General Manager of Alipa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom